Alpha Tom Kodamullil

Group Leader - Applied Semantics

Fraunhofer-Gesellschaft
Country flagGermany

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (8)

1. Abstract Biomedical Knowledge Graphs (BKGs) offer integrative representations of complex biology, yet their utility is compromised by the limitations of current construction methods: manual curation offers high fidelity but is unscalable, whereas purely automated Large Language Model (LLM) approaches often yield broad networks lacking mechanistic granularity. We present KG-Orchestra, an open-source multi-agent framework designed to build specialized, directional, cause-and-effect BKGs by enriching seed graphs. The framework focuses on increasing granularity within specific topics by leveraging Retrieval-Augmented Generation (RAG) to autonomously acquire, validate, and integrate evidence. The system orchestrates specialized agents for retrieval, schema alignment, and triplet validation with explicit, traceable provenance, transforming sparse seeds into dense, high-resolution resources. We evaluated KG-Orchestra on two specialized contexts—the mechanistic link between Nelivaptan and Alzheimer’s Disease (NADKG) and the complex probiotic interactions within the gut–brain axis (ProPreSyn-GBA)—across varying computational budgets. Our benchmarking results demonstrate that Qwen 3 variants deliver superior reasoning performance and that hybrid retrieval strategies significantly enhance evidence relevance. Furthermore, the multi-agent architecture ensures high triplet integrity and biological validity through iterative cross-checking and self-correction. The framework remains computationally flexible, deploying from single laptop GPUs to high-performance clusters. By bridging knowledge gaps and adding context-aware entities, KG-Orchestra increases reliability while validating seed assertions against up-to-date sources. This versatility supports critical downstream applications, including completing missing mechanistic pathways, integrating novel entities for drug repurposing, constructing targeted subgraphs from entity lists, and retroactively validating graph evidence for transparent auditing.

Year:

2026

Biomedical knowledge about the brain increases every day, with a rapidly growing number of scientific publications, datasets, and software tools. While this informational plethora is not merely comprehensible by human beings, recent developments in information science and computational linguistics aim to make this knowledge programmatically accessible by literature mining. However, integrating these semantic methods into neuroimaging standards remains insufficient, hindering researchers from unraveling their full potential. Therefore, we developed the semantic meta-analysis platform The Virtual Brain adapter of semantics (TVBase) that projects biomedical knowledge preserved in over 36 million scientific articles onto a 3D standardized brain. The literature-mining platform SCAIView was used to extract ontologically defined biomedical entities and their associations with brain anatomy from the PubMed database. By querying a specific concept, the association strength with each anatomical term was calculated using entropy. To project the data onto a standardized brain, we created a unique transformation matrix that links over 800 anatomical terms to voxel coordinates of a parcellated standard brain. This novel method of knowledge projection extracts region-specific information about biomedical concepts from the literature to support translational multi-scale approaches to computational neuroscience. The multi-purpose software framework TVBase is openly available as a Python library. It aims for hypothesis-free neuroimaging pattern interpretation, hypothesis generation, and applications in personalized medicine.

Year:

2025

Summary COVID-19 is increasingly recognized as a potential trigger or accelerator of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. To systematically explore the putative molecular and clinical associations between them, we present CBM KG (Causal Biological Mechanisms Knowledge Graph)—a manually curated, comorbidity-centric resource developed within the EU-funded COMMUTE project. CBM KG integrates over 2,800 cause-and-effect or correlative relationships from 63 peer-reviewed publications, highlighting key mechanisms such as viral entry routes, blood-brain barrier alteration, microglial activation, neuroinflammation, and APOE ε4-associated susceptibility. Each relationship in the graph is fully traceable to its source evidence, ensuring transparency and reproducibility. Unlike general-purpose or single disease-focused knowledge graphs, CBM KG is specifically designed to represent causal biological mechanisms spanning both infectious and neurodegenerative processes. By encoding directional, cause-and-effect relationships, it supports the interpretation of clinical co-occurrences through plausible mechanistic links between overlapping disease pathways, offering high-resolution insights at both molecular and clinical levels. Availability and implementation The BEL files, Neo4j database, and Cytoscape visualization files are publicly available at: https://github.com/SCAI-BIO/CBM-Comorbidity-KG .

Year:

2025

Although hundreds of datasets have been published since the beginning of the coronavirus pandemic, there is a lack of centralized resources where these datasets are listed and harmonized to facilitate their applicability and uptake by predictive modeling approaches. Firstly, such a centralized resource provides information about data owners to researchers who are searching datasets to develop their predictive models. Secondly, the harmonization of the datasets supports simultaneously taking advantage of several similar datasets. This, in turn, does not only ease the imperative external validation of data-driven models but can also be used for virtual cohort generation, which helps to overcome data sharing impediments. Here, we present that the COVID-19 data catalogue is a repository that provides a landscape view of COVID-19 studies and datasets as a putative source to enable researchers to develop personalized COVID-19 predictive risk models. The COVID-19 data catalogue currently contains over 400 studies and their relevant information collected from a wide range of global sources such as global initiatives, clinical trial repositories, publications, and data repositories. Further, the curated content stored in this data catalogue is complemented by a web application, providing visualizations of these studies, including their references, relevant information such as measured variables, and the geographical locations of where these studies were performed. This resource is one of the first to capture, organize, and store studies, datasets, and metadata related to COVID-19 in a comprehensive repository. We believe that our work will facilitate future research and development of personalized predictive risk models for COVID-19.

Year:

2024

Motivation Drug repurposing is gaining interest due to its high cost-effectiveness, low risks, and improved patient outcomes. However, most drug repurposing methods depend on drug-disease-target semantic connections of a single drug rather than insights from drug combination data. In this study, we propose SynDRep, a novel drug repurposing tool based on enriching knowledge graphs (KG) with drug combination effects. It predicts the synergistic drug partner with a commonly prescribed drug for the target disease, leveraging graph embedding and machine learning (ML) techniques. This partner drug is then repurposed as a single agent for this disease by exploring pathways between them in the KG. Results HolE was the best-performing embedding model (with 84.58% of true predictions for all relations), and random forest emerged as the best ML model with an area under the receiver operating characteristic curve (ROC-AUC) value of 0.796. Some of our selected candidates, such as miconazole and albendazole for Alzheimer’s disease, have been validated through literature, while others lack either a clear pathway or literature evidence for their use for the disease of interest. Therefore, complementing SynDRep with more specialized KGs, and additional training data, would enhance its efficacy and offer cost-effective and timely solutions for patients. Availability and implementation SynDRep is available as an open-source Python package at https://github.com/SynDRep/SynDRep under the Apache 2.0 License.

Year:

2024

Motivation Drug repurposing is gaining interest due to its high cost-effectiveness, low risks, and improved patient outcomes. However, most drug repurposing methods depend on drug-disease-target semantic connections of a single drug rather than insights from drug combination data. In this study, we propose SynDRep, a novel drug repurposing tool based on enriching knowledge graphs (KG) with drug combination effects. It predicts the synergistic drug partner with a commonly prescribed drug for the target disease, leveraging graph embedding and machine learning techniques. This partner drug is then repurposed as a single agent for this disease by exploring pathways between them in KG. Results HolE was the best-performing embedding model (with 84.58% of true predictions for all relations), and random forest emerged as the best ML model with an ROC-AUC value of 0.796. Some of our selected candidates, such as miconazole and albendazole for Alzheimer’s disease, have been validated through literature, while others lack either a clear pathway or literature evidence for their use for the disease of interest. Therefore, complementing SynDRep with more specialized KG, and additional training data, would enhance its efficacy and offer cost-effective and timely solutions for patients. Availability and Implementation SynDRep is available as an open-source Python package at https://github.com/SynDRep/SynDRep under the Apache 2.0 License.

Year:

2024

Year:

2023

Year:

2023

Collaborators (13)

Reagon Karki

Fraunhofer Institute for Translational Medicine and Pharmacology

GERMANY
View details

Feng Q He

Luxembourg Institute of Health

LUXEMBOURG
View details

Sandra Acosta

Group Leader

University of Barcelona

SPAIN
View details

Tamas Letoha

University of Szeged

HUNGARY
View details

Adithya Sridhar

Assistant Professor

Amsterdam University Medical Centers

NETHERLANDS
View details

Jil Meier

Charité - Universitätsmedizin Berlin

GERMANY
View details

Bertrand Thirion

Institut national de recherche en informatique et en automatique (INRIA)

FRANCE
View details

Ole Pless

Fraunhofer Institute for Translational Medicine and Pharmacology

GERMANY
View details

Ana Solodkin

Professor

University of Texas at Dallas

UNITED STATES
View details

Martin Hofmann-Apitius

Fraunhofer-Institutszentrum Schloss Birlinghoven

GERMANY
View details

Christos Ganos

Director

-

GERMANY
View details

Leon Martin

Charité - Universitätsmedizin Berlin

GERMANY
View details

Marc Jacobs

Deputy Head of Department / Group Leader

Fraunhofer-Gesellschaft

GERMANY
View details